Popular Trials
MEK Inhibitor
AZD6244 + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Detroit, Michigan
This study is evaluating whether a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated
PARP Inhibitor
Long-term Niraparib for Cancer
Recruiting1 awardPhase 2
Atlanta, Georgia
This trial provides continued access to niraparib for patients already receiving it in certain studies and aims to understand its ongoing safety. Niraparib helps stop cancer cells from repairing their DNA, which can kill the cancer. Niraparib is approved for use in ovarian cancer patients who respond to specific treatments.
Imaging
Tomosynthesis vs. Contrast-Enhanced Mammography for Breast Cancer
Recruiting1 award1 criteria
Cranberry Township, Pennsylvania
This trial aims to see if using contrast-enhanced mammography (CEM) can better detect breast cancer in women who have had it before. CEM uses a special dye to make cancerous tissues more visible on the mammogram. The goal is to improve detection rates without significantly increasing false positives. Contrast-enhanced mammography (CEM) is an imaging tool for breast cancer detection that combines conventional mammography with a special dye to improve cancer detection.
DHODH Inhibitor
Leflunomide for Triple Negative Breast Cancer
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing the safety and effectiveness of leflunomide, a daily oral medication, in women with aggressive triple negative breast cancer. The drug aims to block a substance that helps cancer cells grow. The study focuses on women who have already tried other treatments.
Popular Filters
Trials for Ductal Carcinoma Patients
Aromatase Inhibitor
Combination Therapy for Breast Cancer
Recruiting3 awardsPhase 1 & 2
New York, New York
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
PARP Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Hormone Therapy
Endocrine Therapy for Low-Risk Breast Cancer
Recruiting1 awardPhase 2
Saint Louis, Missouri
This trial is testing if hormone therapy alone can effectively treat breast cancer in women aged 70 or older with certain types of tumors. The therapy works by blocking estrogen, which helps stop cancer cells from growing. Researchers believe this approach could be enough to control the cancer without needing more aggressive treatments.
Hormone Therapy
Endocrine Therapy Without Radiotherapy for Breast Cancer
Recruiting1 award13 criteria
Stanford, California
This trial will study whether it's safe to forgo radiation treatment after lumpectomy surgery for postmenopausal women with hormone-positive, Her2-negative tumors who have a low risk of cancer recurrence.
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
Recruiting3 awardsPhase 3
Fayetteville, Arkansas
This trial is comparing two treatments for hormone receptor positive, HER2 negative advanced breast cancer. One group will receive abemaciclib + fulvestrant, and the other will just receive fulvestrant. The study will last about 9 months for each participant.
Trials for LABC Patients
Aromatase Inhibitor
Combination Therapy for Breast Cancer
Recruiting3 awardsPhase 1 & 2
New York, New York
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
PARP Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Hormone Therapy
Endocrine Therapy for Low-Risk Breast Cancer
Recruiting1 awardPhase 2
Saint Louis, Missouri
This trial is testing if hormone therapy alone can effectively treat breast cancer in women aged 70 or older with certain types of tumors. The therapy works by blocking estrogen, which helps stop cancer cells from growing. Researchers believe this approach could be enough to control the cancer without needing more aggressive treatments.
Hormone Therapy
Endocrine Therapy Without Radiotherapy for Breast Cancer
Recruiting1 award13 criteria
Stanford, California
This trial will study whether it's safe to forgo radiation treatment after lumpectomy surgery for postmenopausal women with hormone-positive, Her2-negative tumors who have a low risk of cancer recurrence.
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
Recruiting3 awardsPhase 3
Fayetteville, Arkansas
This trial is comparing two treatments for hormone receptor positive, HER2 negative advanced breast cancer. One group will receive abemaciclib + fulvestrant, and the other will just receive fulvestrant. The study will last about 9 months for each participant.
Trials for Metastatic Patients
Aromatase Inhibitor
Combination Therapy for Breast Cancer
Recruiting3 awardsPhase 1 & 2
New York, New York
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
PARP Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
Recruiting3 awardsPhase 3
Fayetteville, Arkansas
This trial is comparing two treatments for hormone receptor positive, HER2 negative advanced breast cancer. One group will receive abemaciclib + fulvestrant, and the other will just receive fulvestrant. The study will last about 9 months for each participant.
Chemotherapy
Personalized Adaptive Novel Agents for Breast Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
Trials for ER Positive Patients
Aromatase Inhibitor
Combination Therapy for Breast Cancer
Recruiting3 awardsPhase 1 & 2
New York, New York
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
Hormone Therapy
Endocrine Therapy for Low-Risk Breast Cancer
Recruiting1 awardPhase 2
Saint Louis, Missouri
This trial is testing if hormone therapy alone can effectively treat breast cancer in women aged 70 or older with certain types of tumors. The therapy works by blocking estrogen, which helps stop cancer cells from growing. Researchers believe this approach could be enough to control the cancer without needing more aggressive treatments.
Hormone Therapy
Endocrine Therapy Without Radiotherapy for Breast Cancer
Recruiting1 award13 criteria
Stanford, California
This trial will study whether it's safe to forgo radiation treatment after lumpectomy surgery for postmenopausal women with hormone-positive, Her2-negative tumors who have a low risk of cancer recurrence.
Chemotherapy
Personalized Adaptive Novel Agents for Breast Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
Trials for HER2 Positive Patients
Aromatase Inhibitor
Combination Therapy for Breast Cancer
Recruiting3 awardsPhase 1 & 2
New York, New York
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
Chemotherapy
Personalized Adaptive Novel Agents for Breast Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
Chemotherapy
Focused Ultrasound + Gemcitabine for Breast Cancer
Recruiting1 awardPhase 1
Charlottesville, Virginia
This trial will test whether focused ultrasound ablation, low-dose gemcitabine, or a combination of the two can help early-stage breast cancer patients by affecting cells in the immune system. The hypothesis is that the combination of the two will be more effective and have fewer negative side effects than either treatment alone.
CAR T-cell Therapy
CAR T-Cell Therapy for Esophageal Cancer
Recruiting1 awardPhase 1
Basking Ridge, New Jersey
"This trial involves collecting white blood cells from participants, modifying them in a lab to become targeted CAR T cells, and then giving them back to the participants as a therapy. The whole process will take around
Phase 3 Trials
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
Recruiting3 awardsPhase 3
Fayetteville, Arkansas
This trial is comparing two treatments for hormone receptor positive, HER2 negative advanced breast cancer. One group will receive abemaciclib + fulvestrant, and the other will just receive fulvestrant. The study will last about 9 months for each participant.
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant for Early Breast Cancer
Recruiting2 awardsPhase 3
Jonesboro, Arkansas
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
Recruiting2 awardsPhase 3
Chandler, Arizona
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Trials With No Placebo
Aromatase Inhibitor
Combination Therapy for Breast Cancer
Recruiting3 awardsPhase 1 & 2
New York, New York
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
PARP Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Hormone Therapy
Endocrine Therapy for Low-Risk Breast Cancer
Recruiting1 awardPhase 2
Saint Louis, Missouri
This trial is testing if hormone therapy alone can effectively treat breast cancer in women aged 70 or older with certain types of tumors. The therapy works by blocking estrogen, which helps stop cancer cells from growing. Researchers believe this approach could be enough to control the cancer without needing more aggressive treatments.
Hormone Therapy
Endocrine Therapy Without Radiotherapy for Breast Cancer
Recruiting1 award13 criteria
Stanford, California
This trial will study whether it's safe to forgo radiation treatment after lumpectomy surgery for postmenopausal women with hormone-positive, Her2-negative tumors who have a low risk of cancer recurrence.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.